Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1622 1626 1647
This examiner grants 71% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18289214 | COMPOUNDS FOR MODULATING PLATELET-TYPE 12-(S)-LIPOXYGENASE AND METHODS OF USE FOR SAME | Non-Final OA | The Regents of The University of California |
| 18293003 | (3-PIRYDYL)-QUINAZOLINE | Non-Final OA | BASF SE |
| 18272673 | SYNTHESIS OF POLYFLUORINATED ARYL AND HETEROARYL CARBOXAMIDES | Non-Final OA | BASF SE |
| 18481045 | WATER SOLUBLE FLUORESCENT OR COLORED DYES COMPRISING CONJUGATING GROUPS | Non-Final OA | SONY GROUP CORPORATION |
| 18779430 | MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES | Non-Final OA | Hoffmann-La Roche Inc. |
| 18039774 | METHOD FOR PREPARING DEUTERATED ANTHRACENE COMPOUND, REACTION COMPOSITION, DEUTERATED ANTHRACENE COMPOUND AND COMPOSITION | Non-Final OA | LG CHEM, LTD. |
| 17637565 | COMPOSITION FOR PREVENTING OR TREATING BACTERIAL INFECTIOUS DISEASE COMPRISING 4-GINGEROL DERIVATIVE COMPOUND AS ACTIVE INGREDIENT | Non-Final OA | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 18399092 | 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 17419965 | SMALL MOLECULE DEGRADERS OF FKBP12 VIA RECRUITMENT OF VON HIPPEL-LINDAU E3 UBIQUITIN LIGASE (VHL) E3 UBIQUITIN LIGASE, AND USES IN dTAG SYSTEMS | Non-Final OA | DANA-FARBER CANCER INSTITUTE, INC. |
| 17761830 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, AMELIORATING, OR TREATING PROTEINOPATHIES | Final Rejection | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 16980401 | COMPOUNDS AND USES FOR THE TREATMENT AND PREVENTION OF DISEASES AND CONDITIONS ASSOCIATE WITH OR AGGREVATED BY IMPARED MITOPHAGY | Final Rejection | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. |
| 17798440 | FLUORESCENT RHODAMINE DYES WITH ENHANCED CELL PERMEABILITY | Non-Final OA | Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e. V. |
| 17928468 | ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR A | Non-Final OA | Sanford Burnham Prebys Medical Discovery Institute |
| 17755341 | RECYCLE CONTENT ETHYLENE OXIDE OR ALKYLENE GLYCOLS | Non-Final OA | ExxonMobil Product Solutions Company |
| 18296538 | ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | Non-Final OA | ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. |
| 18581289 | PRECURSOR COMPOUNDS FOR PROVIDING RETINOIDS OF THE VATAMIN A5 PATHWAY AND USES THEREOF | Non-Final OA | UNIVERSITÉ DE STRASBOURG |
| 18432751 | STING AGONIST COMPOUNDS AND METHODS OF USE | Non-Final OA | Mersana Therapeutics, Inc. |
| 18561962 | CRYSTALLINE FORM OF TRICYCLIC DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Non-Final OA | ONCONIC THERAPEUTICS INC. |
| 18015309 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Final Rejection | XIZANG HAISCO PHARMACEUTICAL CO., LTD |
| 18496146 | TDO2 and IDO1 Inhibitors | Final Rejection | NewLink Genetics Corporation |
| 17766889 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | Final Rejection | D. E. Shaw Research, LLC |
| 18234826 | 2-S RIMANTADINE AND 2-R RIMANTADINE FOR TREATING CANCER | Non-Final OA | Toragen, Inc. |
| 18134751 | In-Situ crosslinking of 9,9' -spirobifluorene-based compounds for use in optoelectronic and/or in photoelectrochemical devices and manufacture thereof | Non-Final OA | Kaunas University of Technology |
| 18352959 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Ultragenyx Pharmaceutical Inc. |
| 18117295 | TABLET DOSAGE FORMS FOR LIPID-BASED DRUG DELIVERY SYSTEMS | Non-Final OA | ABITEC Corporation |
| 18024010 | USE OF PCSK9 INHIBITOR IN PREPARATION OF PRODUCT FOR TREATING MULTIPLE DISEASES | Non-Final OA | Min CHEN |
| 17430781 | PHARMACEUTICAL COMBINATIONS COMPRISING MEBENDAZOLE AND A STRONG OR MODERATE CYP1A2 INHIBITOR | Non-Final OA | ZEPHAPHARM LTD |
| 17909589 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | Non-Final OA | OM PHARMA SA |
| 17754924 | MACROCYCLIC AND CAGE-LIKE MOLECULE BASED ON BIPHEN[n]ARENE AND DERIVATIVE, SYNTHESIS METHOD AND USE THEREOF | Final Rejection | TIANJIN NORMAL UNIVERSITY |
| 17681383 | SERIES OF HALOGENATED TETRACYCLIC TRITERPENE DERIVATIVES AND THEIR PREPARATION AND APPLICATION | Non-Final OA | SHANGHAI KING-X BIOTECH CO., LTD |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy